{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:40:44Z","timestamp":1770961244063,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.bone.2007.09.001","type":"journal-article","created":{"date-parts":[[2007,9,11]],"date-time":"2007-09-11T07:08:50Z","timestamp":1189494530000},"page":"36-42","source":"Crossref","is-referenced-by-count":69,"title":["Efficacy and safety of risedronate 150\u00a0mg once a month in the treatment of postmenopausal osteoporosis"],"prefix":"10.1016","volume":"42","author":[{"given":"Pierre D.","family":"Delmas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 R.","family":"Zanchetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Racewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude-Laurent","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulema","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle A.","family":"Eusebio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Beary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Matzkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2007.09.001_bib1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2007.09.001_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2007.09.001_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2007.09.001_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2007.09.001_bib5","unstructured":"Actonel label, accessed at http:\/\/www.fda.gov\/cder\/foi\/label\/2007\/020835s025lbl.pdf, May 2007."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2007.09.001_bib6","first-page":"S217","article-title":"The efficacy and tolerability of a monthly dosing regimen of 75\u00a0mg risedronate dosed on 2\u00a0consecutive\u00a0days a month for the treatment of postmenopausal osteoporosis\u20141\u00a0year study results","volume":"18","author":"McClung","year":"2007","journal-title":"Osteoporos. Int."},{"issue":"suppl 2","key":"10.1016\/j.bone.2007.09.001_bib7","first-page":"S210","article-title":"Once-a-month 150\u00a0mg oral risedronate is as effective as oral daily 5\u00a0mg risedronate in postmenopausal osteoporosis: Phase II study results","volume":"17","author":"Ste.-Marie","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2007.09.001_bib8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2007.09.001_bib9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2007.09.001_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(99)00062-5","article-title":"A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone","volume":"106","author":"Miller","year":"1999","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2007.09.001_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S8756-3282(97)00222-6","article-title":"Paget's disease of bone: reduction of disease activity with oral risedronate","volume":"22","author":"Hosking","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.bone.2007.09.001_bib12","unstructured":"Ibandronate label, accessed at www.fda.gov\/cder\/foi\/label\/2005\/021455s001lbl.pdf, May 2007."},{"key":"10.1016\/j.bone.2007.09.001_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejcsup.2006.07.004","article-title":"Ibandronate provides efficacy and safety in the treatment of metastatic bone disease","volume":"Suppl. 4","author":"von Moos","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bone.2007.09.001_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S8756-3282(03)00084-X","article-title":"Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis","volume":"33","author":"Braga","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2007.09.001_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1385\/JCD:5:2:143","article-title":"Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass","volume":"5","author":"Younes","year":"2002","journal-title":"J. Clin. Densitom."},{"issue":"18","key":"10.1016\/j.bone.2007.09.001_bib16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2007.09.001_bib17","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2007.09.001_bib18","unstructured":"EMEA, Committee for Medicinal Products for Human Use. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Adopted November 16, 2006. Accessed at www.emea.europa.eu, May 2007."},{"key":"10.1016\/j.bone.2007.09.001_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstr\u00f6m","year":"2004","journal-title":"Calcif. Tissue Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328207006783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328207006783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:57:37Z","timestamp":1546563457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328207006783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S8756328207006783"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2007.09.001","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}